|
1
|
Kanner AM, Ashman E, Gloss D, Harden C,
Bourgeois B, Bautista JF, Abou-Khalil B, Burakgazi-Dalkilic E,
Llanas Park E, Stern J, et al: Practice guideline update summary:
Efficacy and tolerability of the new antiepileptic drugs II:
Treatment-resistant epilepsy: Report of the Guideline Development,
Dissemination, and Implementation Subcommittee of the American
Academy of Neurology and the American Epilepsy Society. Neurology.
92:82–90. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chen Z, Brodie MJ, Liew D and Kwan P:
Treatment outcomes in patients with newly diagnosed epilepsy
treated with established and new antiepileptic drugs: A 30-year
longitudinal cohort study. JAMA Neurol. 75:279–286. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cooper YA, Pianka ST, Alotaibi NM, Babayan
D, Salavati B, Weil AG, Ibrahim GM, Wang AC and Fallah A:
Repetitive transcranial magnetic stimulation for the treatment of
drug-resistant epilepsy: A systematic review and individual
participant data meta-analysis of real-world evidence. Epilepsia
Open. 3:55–65. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Beamer E, Fischer W and Engel T: The
ATP-gated P2X7 receptor as a target for the treatment of
drug-resistant epilepsy. Front Neurosci. 11(21)2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zhang L, Wang C and Li W: A meta-analysis
of randomized controlled trials on levetiracetam in the treatment
of pediatric patients with epilepsy. Neuropsychiatr Dis Treat.
14:769–779. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Liu JT, Liu B and Zhang H: Surgical versus
medical treatment of drug-resistant epilepsy: A systematic review
and meta-analysis. Epilepsy Behav. 82:179–188. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yun JH: Comparison of lamotrigine and
oxcarbazepine monotherapy for pediatric focal epilepsy: An
observational study. Seizure. 60:123–126. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tombini M, Pellegrino G, Assenza G and
Lazzaro VD: De novo multifocal myoclonus induced by lamotrigine in
a temporal lobe epilepsy case. J Neurol Sci. 373:31–32.
2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Singh T, Kaur T and Goel RK: Adjuvant
quercetin therapy for combined treatment of epilepsy and comorbid
depression. Neurochem Int. 104:27–33. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Luszczki JJ, Wlaz A, Karwan S,
Florek-Luszczki M and Czuczwar SJ: Effects of WIN 55,212-2 mesylate
on the anticonvulsant action of lamotrigine, oxcarbazepine,
pregabalin and topiramate against maximal electroshock-induced
seizures in mice. Eur J Pharmacol. 720:247–254. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Thelengana A, Shukla G, Srivastava A,
Singh MB, Gupta A, Rajan R, Vibha D, Pandit AK and Prasad K:
Cognitive, behavioural and sleep-related adverse effects on
introduction of levetiracetam versus oxcarbazepine for epilepsy.
Epilepsy Res. 150:58–65. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gorman JM, Korotzer A and Su G: Efficacy
comparison of escitalopram and citalopram in the treatment of major
depressive disorder: Pooled analysis of placebo-controlled trials.
CNS Spectr. 7 (Suppl 1):40–44. 2002.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gill SJ, Lukmanji S, Fiest KM, Patten SB,
Wiebe S and Jetté N: Depression screening tools in persons with
epilepsy: A systematic review of validated tools. Epilepsia.
58:695–705. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Carneiro AM, Fernandes F and Moreno RA:
Hamilton depression rating scale and montgomery-asberg depression
rating scale in depressed and bipolar I patients: psychometric
properties in a Brazilian sample. Health Qual Life Outcomes.
13(42)2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wijnen BF, Mosweu I, Majoie MH, Ridsdale
L, de Kinderen RJ, Evers SM and McCrone P: A comparison of the
responsiveness of EQ-5D-5L and the QOLIE-31P and mapping of
QOLIE-31P to EQ-5D-5L in epilepsy. Eur J Health Econ. 19:861–870.
2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Peng WF, Fan F, Li X, Zhang QQ, Ding J and
Wang X: Different behavioral and pathological changes between
epilepsy-associated depression and primary depression models.
Epilepsy Behav. 83:212–218. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rider FK, Danilenko OA, Grishkina MN,
Kustov GV, Akzhigitov RG, Lebedeva AV and Gekht AB: Depression and
epilepsy: Comorbidity, pathogenetic similarity, and principles of
treatment. Neurosci Behav Physiol. 48:78–82. 2018.
|
|
18
|
Josephson CB, Lowerison M, Vallerand I,
Sajobi TT, Patten S, Jette N and Wiebe S: Association of depression
and treated depression with epilepsy and seizure outcomes: A
multicohort analysis. JAMA Neurol. 74:533–539. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mula M: Depression in epilepsy. Curr Opin
Neurol. 30:180–186. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Johannessen Landmark C, Baftiu A, Tysse I,
Valsø B, Larsson PG, Rytter E and Johannessen SI: Pharmacokinetic
variability of four newer antiepileptic drugs, lamotrigine,
levetiracetam, oxcarbazepine, and topiramate: A comparison of the
impact of age and comedication. Ther Drug Monit. 34:440–445.
2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Glauser TA: Oxcarbazepine in the treatment
of epilepsy. Pharmacother J Hum Pharmacol Drug Ther. 21:904–919.
2012.
|
|
22
|
D'Anto J, Wnuk W, Rossetti AO, Decosterd
LA, Buclin T and Novy J: Lamotrigine serum levels: Ceiling effect
in people with epilepsy in remission? Epilepsy Behav. 74:41–44.
2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhang M, Ming LI, Zhang X, et al:
The clinical efficacy of lamotrigine in the treatment of epilepsy
with depression and the influence on cognitive function. Chinese
Journal of Medicinal Guide, 2017.
|
|
24
|
Martinović Z, Buder N, Milovanović M and
Velićković R: Antiepileptic, behavioral, and antidepressant effects
of adjuvant lamotrigine therapy in drug-resistant epilepsy.
Vojnosanit Pregl. 61:485–490. 2004.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Azorin JM, Llorca PM, Despiegel N and
Verpillat P: Escitalopram is more effective than citalopram for the
treatment of severe major depressive disorder. Encephale.
30:158–166. 2004.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kutluay E, McCague K, D'Souza J and
Beydoun A: Safety and tolerability of oxcarbazepine in elderly
patients with epilepsy. Epilepsy Behav. 4:175–180. 2003.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Sunwoo JS, Park BS, Ahn SJ, Hwang S, Park
CY, Jun JS, Kim DW, Lee ST, Jung KH, Park KI, et al: Three-year
retention rates of levetiracetam, topiramate, and oxcarbazepine: A
retrospective Hospital-based Study. Clin Neuropharmacol. 40:56–62.
2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Reilly C, Atkinson P, Das KB, Chin RF,
Aylett SE, Burch V, Gillberg C, Scott RC and Neville BG:
Neurobehavioral comorbidities in children with active epilepsy: A
population-based study. Pediatrics. 133:e1586–e1593.
2014.PubMed/NCBI View Article : Google Scholar
|
